INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/600,786	Inventor Alexandros Makriyannis et al	
	Title: Cannabimimetic Lipid Amides as Useful Medications		
	Filing Date 07/21/2000	Group Art Unit 1621	Docket No. UCONAP/145/PC/US

UNITED STATES PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Name	Class

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Country	Name	Translation
	WO 94/12466 A	06/1994		Yissum Research Development Co.	English

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

Examiner Initial	
	Supplementary European Search Report for EP Application No. 99 96 1838 dated November 1, 2004
	Hanus, L. et al, "Two New Unsaturated Fatty Acid Ethanolamides in Brain That Bind to the Cannabinoid Receptor" JOURNAL OF MEDICINAL CHEMISTRY, vol. 36, no. 20, 1993, pp. 3032-3034
	Mechoulam, R. et al, "Towards cannabinoid drugs – revisited" PROGRESS IN MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 35, 3 July 1998, pp. 199-243

Examiner	Date Considered
	8/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

G:\AYR saved docs\Filing Docs\Uconap\uconap.145.pc.us\12-04 IDS and form1449 info from foreign counterpart.doc

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/600,786	Inventor Alexandros Makriyannis et al	
	Title Cannabimimetic Lipid Amides as Useful Medications		
	Filing Date 07/21/2000	Group Art Unit 1614	Docket No. UCONAP/145/PC/US

UNITED STATES PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Name	Class
JP	09/698,071	10/30/00	Fride et al, (copy not included, this is the parent application for US Publication No. 2002/0173528, enclosed herewith)	
	09/701989	**6/9/99**	***1* Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 99/64389 enclosed herewith)**	
	10/110865	10/18/00	Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/29007 enclosed herewith)	
	10/110830	10/18/00	Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/28329 enclosed herewith)	
	10/110812	10/18/00	Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/28497 enclosed herewith)	
	10/110862	**10/18/00**	***1* Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/28498 enclosed herewith)**	
	10/111059	10/18/00	Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 01/28557 enclosed herewith)	
	10/493093	10/28/02	Makriyannis et al (copy not included, this is the U.S. National Phase of the Int'l Application published as WO 03/35005 enclosed herewith)	
	10/647544	8/25/03	Makriyannis et al	
	10/790498	3/1/04	Makriyannis et al	

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/600,786	Inventor Alexandros Makriyannis et al	
	Title Cannabimimetic Lipid Amides as Useful Medications		
	Filing Date 07/21/2000	Group Art Unit 1614	Docket No. UCONAP/145/PC/US

	2002/0119972	8/29/02	Leftheris et al	
	2002/0173528	11/21/02	Fride et al	
	2003/0120094	6/26/03	Makriyannis et al	
	2003/0149082	**8/7/03**	***1* Makriyannis et al**	
	2004/0077649	4/22/04	Makriyannis et al	
	2004/0077851	4/22/04	Makriyannis et al	
	2004/0087590	5/6/04	Makriyannis et al	
	3041343	6/26/62	Jucker et al	
	3465024	**9/2/69**	***1* Brownstein et al**	
	3573327	3/30/71	Miyano	
	3577458	**5/4/71**	***1* Brownstein et al**	
	3656906	4/18/72	Bullock	
	3838131	9/24/74	Gauthier	
	3886184	5/27/75	Matsumoto et al	
	3897306	7/29/75	Vidic	
	3915996	10/28/75	Wright	
	3928598	12/23/75	Archer	
	3944673	3/16/76	Archer	
	3946029	3/23/76	Descamps et al	
	3953603	4/27/76	Archer	
	4036857	7/19/77	Razdan et al	
	4054582	10/18/77	Blanchard et al	
	4087545	5/2/78	Archer et al	
	4087546	5/2/78	Archer et al	
	4087547	5/2/78	Archer et al	
	4088777	5/9/78	Archer et al	
	4102902	7/25/78	Archer et al	
	4152450	5/1/79	Day et al	
	4171315	10/16/79	Ryan et al	
	4176233	11/27/79	Archer et al	
	4179517	12/18/79	Mechoulam	
	4188495	2/12/80	Althuis et al	
	4208351	6/17/80	Archer et al	
	4278603	7/14/81	Thakkar et al	
	4282248	8/4/81	Mechoulam et al	
	4382943	5/10/83	Winter et al	
	4395560	7/26/83	Ryan	

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/600,786	Inventor Alexandros Makriyannis et al	
	Title Cannabimimetic Lipid Amides as Useful Medications		
	Filing Date 07/21/2000	Group Art Unit 1614	Docket No. UCONAP/145/PC/US

	4497827	**2/5/85**	***1* Nelson**	
	4550214	10/29/85	Mehta	
	4758597	7/19/88	Martin et al	
	4812457	**3/14/89**	***1* Narumiya**	
	4876276	10/24/89	Mechoulam	
	4885295	12/5/89	Bell et al	
	5053548	10/1/91	Tanaka et al	
	5068234	11/26/91	D'Ambra et al	
	5147876	9/15/92	Mizuchi et al	
	5223510	6/29/93	Gubin et al	
	5284867	2/8/94	Kloog	
	5324737	6/28/94	D'Ambra et al	
	5434295	7/18/95	Mechoulam et al	
	5440052	8/8/95	Makriyannis et al	
	5462960	10/31/95	Barth et al	
	5489580	2/6/96	Makriyannis et al	
	5521215	5/28/96	Mechoulam	
	5532237	7/2/96	Gallant et al	
	5538993	7/23/96	Mechoulam	
	5576436	**11/19/96**	***1* McCabe et al**	
	5605906	2/25/97	Lau	
	5607933	3/4/97	D'Ambra et al	
	5618955	**4/8/97**	***1* Mechoulam et al**	
	5624941	4/29/97	Barth et al	
	5635530	6/3/97	Mechoulam	
	5688825	**11/18/97**	***1* Makriyannis et al**	
	5747524	5/5/98	Cullinan et al	
	5744459		Makriyannis et al	
	5804601	**9/8/98**	***1* Kato et al (appears equivalent to EP0737671)**	
	5817651	10/6/98	D'Ambra et al	
	5872148	2/16/99	Makriyannis et al	
	5874459	**2/23/99**	***1* Makriyannis et al**	
	5925628	**7/20/99**	***1* Lee et al**	
	5925768	7/20/99	Barth et al	
	5932610	8/3/99	Shohami et al	

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/600,786	Inventor Alexandros Makriyannis et al	
	Title Cannabimimetic Lipid Amides as Useful Medications		
	Filing Date 07/21/2000	Group Art Unit 1614	Docket No. UCONAP/145/PC/US

	5948777	9/7/99	Bender et al	
	6013648	1/11/00	Rinaldi et al (appears equivalent to FR2735774)	
	6028084	2/22/00	Barth et al	
	6096740	9/1/00	Mechoulam	
	6127399	10/3/00	Yuan	
	6166066	12/26/00	Makriyannis et al	
	6284788	10/4/01	Mittendorf et al (appears equivalent to EP860168)	
	6391909	**5/21/02**	***1* Makriyannis et al**	
	6579900	**6/17/03**	***1* Makriyannis et al**	
	6610737	8/26/03	Garzon et al	

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Country	Name	Translation
	EP0276732	8/3/88	EP	Hoffman La Roche	
	EP0444451	9/4/91	EP	Sterling Drug (English bibliography, abstract and cover page, appears equivalent to US5068234 which is also cited)	
	EP0471609	6/29/93	EP	Gubin et al, in French, front page only (English bibliography and abstract, appears equivalent to US5223510)	
	EP0737671	**10/16/96**	**EP**	***1* Takeda Chemical Industries, front page only (bibliography, appears equivalent to US 5804601)**	
	EP0860168	9/4/01	EP	Mittendorf et al, in German, front page only (including English bibliography, appears equivalent to US6284788)	

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/600,786	Inventor Alexandros Makriyannis et al	
	Title Cannabimimetic Lipid Amides as Useful Medications		
	Filing Date 07/21/2000	Group Art Unit 1614	Docket No. UCONAP/145/PC/US

	FR2240003	5/27/75	FR	Matsumoto et al, in French (including English bibliography and abstract, appears equivalent to US3886184)	
	FR2735774	1/11/00	FR	Barth et al, in French (including English bibliography and abstract, appears equivalent to US6013648)	
	GB2027021A	2/13/80	GB	Mechoulam et al, in English (appears equivalent to US4282248)	
	JP2304080	12/17/90	JP	Nakayama Hajime et al, in Japanese (including English bibliography and abstract)	
	JP57098228	6/18/82	JP	Noda et al, in Japanese (including English bibliography and abstract)	
	WO 01/28329	4/26/01		Makriyannis et al, in English	
	WO 01/28497	4/26/01		Makriyannis et al, in English	
	WO 01/28498	**4/26/01**		***1* Makriyannis et al, in English**	
	WO 01/28557	4/26/01		Makriyannis et al, in English	
	WO 01/29007	4/26/01		Makriyannis et al, in English	
	WO 01/32169	5/10/01		Fride et al, in English	
	WO 01/58869	8/16/01		Pandit et al, in English, first page only (including bibliography and abstract, appears equivalent to US2002/0119972)	
	WO 02/058636	8/1/02		Makriyannis et al, in English	
	WO 02/060447	8/8/02		Makriyannis et al, in English	
	WO 03/005960	1/23/03		Makriyannis et al, in English	
	WO 03/020217	3/13/03		Makriyannis et al , in English	
	WO 03/035005	5/1/03		Makriyannis et al, in English	
	WO 03/063758	8/7/03		Garzon et al, in English	
	WO 03/064359	8/7/03		Garzon et al, in English	

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/600,786	Inventor Alexandros Makriyannis et al	
	Title Cannabimimetic Lipid Amides as Useful Medications		
	Filing Date 07/21/2000	Group Art Unit 1614	Docket No. UCONAP/145/PC/US

	WO 97/00860	1/9/97		Rinaldi et al, in French (including English bibliography and abstract, appears equivalent to US6013648)	
	WO 99/57106	11/11/99		Makriyannis et al, in English	
	WO 99/57107	11/11/99		Makriyannis et al, in English	
	WO 99/64389	**12/16/99**		***1*** **Makriyannis et al, in English**	

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

Examiner Initial	
	***1* Abadji V., Lin S., Taha G., Griffin G., Stevenson L.A., Pertwee R.G., Makriyannis A.; "(R)-Methanadamide: a chiral novel anandamide possessing higher potency and metabolic stability"; J. Med. Chem.; 37(12); 1889-1893; 1994; CODEN: JMCMAR; ISSN: 0022-2623; XP002040932**
	Alo, B.I.; Kandil, A.; Patil, P. A.; Sharp, M. J.; Siddiqui, M. A.; and Snieckus, V. Sequential Directed Ortho Metalation-Boronic Acid Cross-Coupling Reactions. A general Regiospecific Route to Oxygenerated Dibenzo[b,d]pyran-6-ones Related to Ellagic Acid, J. Org. Chem. 1991, 56, 3763-3768
	**** Archer et al; "cannabinoids, synthesis approaches to 9-ketocannabinoids."; J. Org. Chem.; vol. 42; no. 13; 2277-2284; (1977)*
	Arnone M., Maruani J., Chaperon P, et al, Selective inhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1) receptors, Psychopharmacal, (1997) 132, 104-106. **(abstract only)**
	***1* Barnett-Norris et al; "Exploration of biologically relevant conformations of anandamide, . . ."; J. Med. Chem.; vol. 41; 4861-4872; 1998**
	Beak, P.; and Brown, R A., The Tertiary Amide as an Effective Director of Ortho Lithiation, J. Org. Chem. 1982, 47, 34-36
	Belgaonkar et al; "synthesius of isocoumarins"; Indian J. Chem; vol. 13; no. 4; 336-338; 1975 **(abstract only)**
	***1* Beltramo M., Stella N., Calignano A., Lin S. Y., Makriyannis A., Piomelli D; "Functional Role Of High-Affinity Anandamide Transport, as Revealed By Selective Inhibition"; Science; vol. 277; 1094-1097; 1997**

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/600,786	Inventor Alexandros Makriyannis et al	
	Title Cannabimimetic Lipid Amides as Useful Medications		
	Filing Date 07/21/2000	Group Art Unit 1614	Docket No. UCONAP/145/PC/US

20	***1* Beltramo M., Stella N., Calignano A., Lin S. Y., Makriyannis A., Piomelli D; "Identification and Functional Role of High Affinity Anandamide Transport"; The Neurosciences Institute (1 page)**
	***1* Beltramo M., Piomelli D; "Anandamide Transport Inhibition by the Vanilloide Agonist Olvanil"; Europeean J. of Pharmacology; (1999); 364(1); 75-78 (abstract only)**
	Berdyshev EV, Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids. 2000 Nov; 108(1-2):169-90
	***1* Berglund et al; "Structural requirements for arachidonylethanolamide interaction with CB1 and CB2 cannabinoid receptors: . . ."; Prostanglandins, leukotrienes ands essential fatty acids; 59(2); 111-118; (1998). (abstract only)**
	Bodnar, V.N., Lozinskii, M.O., Pel'kis, P.S.; "Synthesis fo 2,5-disubstituted 1,3,4-oxadiazoles and 1,4-dihydro-1,2,4,5-tetrazines"; Ukrainskii Khimicheskii Zhurnal (Russian Edition); 48(12); 1308-1311; 1982 **(abstract only)**
	Bracey, M et al, Structural Adaptations in a Membrane Enzyme That Terminates Endocannabinoid Signaling. Science 2002; 298(5599): 1793-1796
	Brenneisen R, Pgli A, Elsohly MA, Henn V. Spiess Y: The effect of orally and rectally administered Δ9 – tetrahydrocannabinol on spasticity, a pilot study with 2 patients. Int. J. Clin Pharmacol Ther. (1996) 34:446-452. **(abstract only)**
	Brotchie JM: Adjuncts to dopamine replacement a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov. Disord. (1998)13:871-876. **(abstract only)**
	Brown et al; "Synthesis and hydroboration of (-)-2-phenylapopinene, Comparison of mono(2-phenylapoisopinocampheyl)borane with its 2-methyl and 2-ethyl analogues for the chiral hydroboration of representative alkenes"; J. Org. Chem.; 55(4); 1217-1223; (1990)
	Buckley NE, McCoy KI, Mpzey E et al, "Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor"; Eur. J Pharmacol (2000) 396:141-149.
	Burstein et al; "detection of cannabinoid receptors . . ."; Biochem. Biophys. Res. Commun.; vol. 176(1); 492-497; 1991 **(abstract only)**
	Busch-Peterson et al; "Unsaturated side chain beta-11-hydroxyhexahydrocannabinol analogs"; J. Med. Chem.; 39; 3790-3796; (1996)

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/600,786	Inventor Alexandros Makriyannis et al	
	Title Cannabimimetic Lipid Amides as Useful Medications		
	Filing Date 07/21/2000	Group Art Unit 1614	Docket No. UCONAP/145/PC/US

20	Calignano A, La Rana G. Diuffrida A, Piomelli D; "Control of pain initiation by endogenous cannabinoids"; Nature (1998) 394:277-291. **(abstract only)**
	***1* Calignano A., La Rana G., Beltramo, M., Makriyannis A., Piomelli D; "Potentiation of Anandamide Hypotension by the Transport Zinhibitor, AM404"; Eur. J. Pharmacol.; 1997; 337 R1-R2**
	***1* Calignano A., La Rana G., Makriyannis A., Lin. S., Beltramo M., Piomelli D; "Inhibition of Intestinal Motility by Anandamide, an Endogenous Cannabinoid"; Eur. J. Pharmacol.; 1997; 340 R7-R8**
	Campbell FA et al; "Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review"; BMJ. 2001 Jul 7;323(7303):13-6
	Charalambous A. et al; "5'-azido Δ8-THC: A Novel Photoaffinity Label for the Cannabinoid Receptor"; J. Med. Chem., 35, 3076 - 3079 (1992)
	Charalambous A. et al; "Pharmacological evaluation of halogenated . . ."; Pharmacol. Biochem. Behav.; vol. 40; no. 3; 509-512; 1991
	Cheng et al; "Relationship Between the Inhibition Constant (Ki) and the concentration of Inhibitor which causes 50% Inhibition (IC50) of an Enzymatic Reaction"; Biochem. Pharmacol., 22, 3099-3102, (1973) **(abstract only)**
	***1* Cherest M., Luscindi X.; "The action of acetyl chloride and of acetic anhydride on the lithium nitronate salt of 2-phenylnitroethane . . ."; Tetrahedron; 42(14); 3825-3840; 1986; in French with English abstract**
	***1* Cherest M., Lusinchi X.; "A novel electrophilic N-amidation via electron deficient complexes: action of ferric chloride on N-acetyloxyamides"; Tetrahedron Letters; 30(6); 715-718; 1989**
	Colombo G, Agabio R, Diaz G. et al; "Appetite suppression and weight loss after the cannabinoid antagonist SR141716"; Life Sci. (1998) 63-PL13-PL117. **(abstract only)**
	***1* Compton D.R. et al; "Pharmacological Profile Of A Series Of Bicyclic Cannabinoid Analogs: Classification as Cannabimimetic Agents"; J. Pharmacol. Exp. Ther.; 260; 201-209; 1992. (abstract only)**
	Compton et al; "Synthesis and pharmacological evaluation of ether and related analogues of delta8-. delta9- and delta9,11-tetrahydrocannabinol"; J. Med. Chem; vol. 34; no. 11; 3310-3316; 1991
	Consroe P, Musty R, Rein J, Tillery W, Pertwee R; "The perceived effects of smoked cannabis on patents with multiple sclerosis"; Eur. Neurol. (1997) 38-44-48. **(abstract only)**

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/600,786	Inventor Alexandros Makriyannis et al	
	Title Cannabimimetic Lipid Amides as Useful Medications		
	Filing Date 07/21/2000	Group Art Unit 1614	Docket No. UCONAP/145/PC/US

	Coxon et al; "Derivatives of nopinone"; Aust. J. Chem.; 23; 1069-1071; (1970) **(abstract only)**
	Crawley et al; "Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents"; Pharmacology Biochemistry and Behavior; vol. 46; 967-972; 1993
	D'Ambra et al; "C-attached aminoalkylindoles: potent cannabinoid mimetics"; Bioorg. & Med. Chem. Lett., 1996, 6(1), 17-22
	1* *** D'Amour F.E. et al; "A Method For Determining Loss Of Pain Sensation"; J. Pharmacol. Exp. Ther.; 72; 74-79; 1941
	***1* Demuynck L. et al; "Rearrangement of Indolo[2,3-a]quinolizidines to derivatives with E-azaaspidospermane skeleton"; Tetrahedron Letters; 30(6) 710-722; 1989; in French with English abstract**
	DePetrocellis L, Melck D, Palmisano A. et al; "The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation"; Proc. Natl. Acad. Sci. USA (July 1998) 95:8375-8380.
	***1* Desarnaud F., Cadas H., Piomelli D.; "Anandamide amidohydrolase activity in rat brain microsomes"; J. Biol. Chem.; 270; 6030-6035; (1995)**
	***1* Deutsch D.G. et al; "Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to cannabinoid receptor"; Biochem. Biophys. Res. Commun. 231(1); 217-221; 1997; CODEN: BBRCA9; ISSN:0006-291X; XP002040933**
	***1* Deutsch D.G., Chin S.A.; "Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist"; Biochemical Pharmacology; 46(5); 791-796; 1993**
	Devane, W.A. et al; "Determination and Characterization of a Cannabinoid Receptor in a Rat Brain"; Mol. Pharmacol., 34, 605 - 613 (1988). **(abstract only)**
	Di Marzo, V., Melck, D., Bisogno, T., DePetrocellis, L.; "Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action"; Trends Neurosci. (1998) 21:521 - 528.
	***1* Di Marzo, V., Bisogno, T., Melck, D., Ross, R., Brockie, H., Stevenson, L., Pertwee, R., DePetrocellis, L., "Interactions between synthetic vanilloids and the endogenous cannabinoid system"; FEBS Letters; (1998); 437(3); 449-454. (abstract only)**
	Dodd, P.R. et al, A Rapid Method for Preparing Synaptosomes: Comparison with Alternative Procedures, Brain Res., 226, 107 - 118 (1981). **(abstract only)**

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/600,786	Inventor Alexandros Makriyannis et al	
	Title Cannabimimetic Lipid Amides as Useful Medications		
	Filing Date 07/21/2000	Group Art Unit 1614	Docket No. UCONAP/145/PC/US

20	Dominiami et al; "Synthesis of 5-(tert-Alkyl)resorcinols"; J. Org. Chem. 42(2); 344-346; (1977)
	Drake et al, "classical/nonclassical hybrid cannabinoids"; J. Med. Chem.; vol. 41(19); 3596-3608 (1998)
	Edery et al; "Activity of novel aminocannabinoids in baboons"; J. Med. Chem.; 27; 1370-1373 (1984)
	Eissenstat et al; "Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics"; J. Med. Chem. 1995, Vol. 38, No. 16, pp. 3094-3105; XP 000651090
	Fahrenholtz, K. E., Lurie, M. and Kierstead, AR. W.; "The Total Synthesis of dl-Δ9-Tetrahydrocannabinol and Four of Its Isomers"; J. Amer. Chem. Soc. 1967, 89(23), 5934-5941
	Fahrenholtz; "The synthesis of 2 metabolites of (-)-delta eight-tetrahydrocannabinol"; J. Org. Chem.; vol. 37(13); 1972; XP002111824
	Fisera, L., Kovac, J., Lesco, J., Smahovsky, V.; "Furan derivatives. Part CLVI. 1,3-dipolar cycloadditions of heterocycles. V. Reaction of C-acetyl-N-phenylnitrilimine with furan derivatives"; Chemicke Zvesti; 35(1); 93-104 1981 **(abstract only)**
	***1* Fride, E. & Mechoulam, R.; "Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent"; European Journal of Pharmacology, vol. 231; 313-314; 1993.**
	Galiegue S et al. ; "Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations"; Eur J Biochem.; 1995 Aug 15;232(1):54-61. **(abstract only)**
	Gareau, Y.; Dufresne, C.; Gallant, M.; Rochette, C.; Sawyer, N.; Slipetz, D. M.; Tremblay, N.; Weech, P. K.; Metters, K. M.; Labelle, M.; "Structure activity relationships of tetrahydrocanabinol analogs on human cannabinoid receptors"; Bioorg. Med. Chem. Lett. 1996, 6(2), 189-194
	Gold et al; "A comparison of the discriminative stimulus properties of delta9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys"; J. Pharmacol. Exp. Ther.; vol. 262(2); 479-486; 1992
	Green K.; "Marijuana smoking vs. cannabinoids for glaucoma therapy."; Arch. Ophthamol. (1998) Nov. 116(11); 1433-1437. **(abstract only)**
21	Hampson, A.J., Grimaldi M. Axpirod J. Wink D; "Cannabidiol and (-) Δ9 tetrahydrocannabinol are neuroprotective antioxidants"; Proc. Natl Acad Sci. USA (July 1998) 95; 8268-8273.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/600,786	Inventor Alexandros Makriyannis et al	
	Title Cannabimimetic Lipid Amides as Useful Medications		
	Filing Date 07/21/2000	Group Art Unit 1614	Docket No. UCONAP/145/PC/US

	Hargreaves, K. et al; "A new sensitive method for measuring thermal nociception in cutaneous hyperalgesia"; Pain; 32; 77-88; (1988) **(abstract only)**
	*** *Hemming M, Yellowlees PM; "Effective treatment of Tourette's syndrome with marijuana"; J. Psychopharmacol, (1993) 7:389-391.*
	Herzberg U, Eliav E, Bennett GJ, Kopin IJ; "The analgesic effects of R(+) WIN 55,212-2 mesylate, a high affinity cannabinoid agonist in a rat model of neuropathic pain"; Neurosci. Letts. (1997) 221; 157-160.
	***1* Hillard C. J.; Edgemond, W. S., Jarrahian W., Campbell, W. B; "Accumulation of N-Arachidonoylethanolamine (Anandamide) into Cerebellar Granule Cells Occurs via Facilitated Diffusion"; Journal of Neurochemistry; 69; 631-638 (1997)**
	***1* Horrevoets A.J.G et al; "Inactivation of escherichia coli outer membrane phospholipase A by the affinity label hexadecanesulfonyl fluoride"; Eur. J. Biochem.; 198; 247-253; 1991**
	***1* Horrevoets A.J.G et al; "Inactivation of reconstituted escherichia coli outer membrane phospholipase A by membrane-perturbing peptides results in an increased reactivity towards the affinity label hexadecanesulfonyl fluoride"; Eur. J. Biochem.; 198; 255-261; 1991**
	Howlett et al; "Azido and isothicyanato substituted aryl pyrazoles bind covalently to the CB1 cannabinoid receptor and impair signal transduction"; Journal of Neurochemistry; vol. 74(5) (2000) 2174-2181; XP001097394
	Howlett et al; "Stereochemical effects of 11-OH-delta 8 tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor"; Neuropharmacology; vol. 29(2); 161-165; 1990
	Huffman et al; "3-(1',1'-dimethylbutyl)--deoxy-delta 8THC and related compounds: synthesis of selective ligands for the CB2 receptor"; Bioorganic and Medicinal Chemistry; vol. 7; 2905-2914; (1999)
	Huffman et al; "Stereoselective synthesis of the epimeric delta 7-tetrahydocannabinols"; tetrahedron; vol. 51(4); 1017-1032; (1995)
	Huffman et al; "Synthesis of 5',11 dihydroxy delta 8 tetrahydrocannabinol"; Tetrahedron, vol. 53(39), pp 13295-13306 (1997)
	Huffman et al; "Synthesis of a tetracyclic, conformationally constrained analogue of delta8-THC"; Bioorganic & Medicinal Chemistry; vol. 6(12); 2281-2288; 1998; XP002123230
	Huffman et al; "Synthesis of both enantiomers of Nabilone from a common intermediate. Enantiodivergent synthesis of cannabinoids"; J. Org. Chem.; 1991, 56, 2081-2086

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/600,786	Inventor Alexandros Makriyannis et al	
	Title Cannabimimetic Lipid Amides as Useful Medications		
	Filing Date 07/21/2000	Group Art Unit 1614	Docket No. UCONAP/145/PC/US

20		Joy JE, Wagtson SJ, Benson JA; "Marijuana and Medicine Assessing the Science Base"; National Academy Press, Washington, DC, USA (1999). **(abstract only)**
		Kaminski NE; "Regulation of the cAMP cascade, gene expression and immune function by cannabinoid receptors"; J Neuroimmunol. 1998 Mar 15;83(1-2):124-32
		***1* Kawase M. et al; "Electrophilic aromatic substitution with N-methoxy-N-acylnitrenium ions generated from N-chloro-N-methoxyamides: synthesis of nitrogen heterocyclic compounds bearing a N-methoxyamide group"; J. Org. Chem.; 54; 3394-3403; 1989**
		***1* Khanolkar A., Abadji V., Lin S., Hill W., Taha G., Abouzid K., Meng Z., Fan P., Makriyannis A.; "Head group analogues of arachidonylethanolamide, the endogenous cannabinoid ligand"; J. Med. Chem.; vol. 39(22); 4515-4519; (1996)**
		Khanolkar et al; "Molecular probes for the cannabinoid receptors"; Chemistry and Physics of Lipids; 108; 37-52; (2000)
		Klein T.W. et al, "The cannabinoid system and cytokine network"; Proc Soc Exp Biol Med. 2000 Oct; 225(1):1-8; **(abstract only)**
		Klein TW et al, "Cannabinoid receptors and immunity"; Immunol Today; 1998 Aug; 19(8):373-81
		***1* Koutek B. et al; "Inhibitors of arachidonyl ethanolamide hydrolysis"; J. Biol. Chem.; 269(37); 22937-40; 1994; CODEN: JBCHA3; ISSN: 0021-9258; XP002040931**
		Kumar RN, et al; "Pharmacological actions and therapeutic uses of cannabis and cannabinoids"; Anesthesia, 2001, 56: 1059-1068 **(abstract only)**
		Lan, R et al; "Structure activity relationships of pyrazole derivatives as cannabinoid receptor antagonists"; J. Med. Chem.; vol. 42(4); 769-776; (1999)
		***1* Lang, W. et al; "Substrate Specificity and Stereoselectivity of Rat Brain Microsomal Anandamide Amidohydrolase"; J. Med. Chem.; vol. 42(5); 896-902; (1999)**
		Lavalle et al; "Efficient conversion of (1R, 5R)-(+)-alpha-pinene to (1S, 5R)-(-)-nopinene"; J. Org. Chem.; vol. 51(8); 1362-1365; (1986)
		***1* Lin S., Khanolkar A., Fan P., Goutopolous A., Qin C., Papahadjis D., Makriyannis A.; "Novel Analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 Cannabinoid Receptors and Metabolic Stability"; J. Med. Chem.; vol. 41; 5353; 1998**

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/600,786	Inventor Alexandros Makriyannis et al	
	Title Cannabimimetic Lipid Amides as Useful Medications		
	Filing Date 07/21/2000	Group Art Unit 1614	Docket No. UCONAP/145/PC/US

	Loev, B., Bender, P. E., Dowalo, F., Macko, E., and Fowler, P.; "Cannabinoids. Structure-Activity Studies Related to 1,2-Dimethylheptyl Derivatives"; J. Med. Chem.; vol. 16(11); 1200-1206; 1973
	Lozinskii, M.O., Bodnar, V.N., Konovalikhin, S.V., D'yachenko, O.A., Atovmyan, L.O.; "Unusual transformations of arylhydrazonoyl chlorides of oxalic acid ethyl ester"; Izvestiya Akademii Nauk SSSr, Seriya Khimicheskaya; 11; 2635-2637; 1990 **(abstract only)**
	Ludt, R.E. et al; "A comparison of the synthetic utility of n-butyllithium and lithium diisopropylamide in the metalations of N,N-dialkyltouamides"; J. Org. Chem.; 38(9); 1668-1674 (1973)
	*** *Maccarron M., Endocannabinoids and their actions. Vitamins and Hormones 2002;65:225-255*
	1 **Mackie K., Devane W.A., Hille B.; "Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells"; Mol. Pharmacol; 44; 498-0503 (1993)**
	*** *Markwell, M.A.K., S.M. Haas, L.L. Bieber, and N.E. Tolbert.; "A modification of the Lowry procedure to simplify protein determination in the membrane and lipoprotein samples." 1978; Anal. Biochem. 87:206-210.*
	Martin et al; "Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs"; Pharmacol. Biochem. Behav.; vol. 40(3); 471-478; 1991
	Martyn CN. Illis LS, Thom J.; "Nabilone in the treatment of multiple sclerosis"; Lancet (1995) vol. 345; pp. 579.
	Matsumoto et al; "Cannabinoids 1.1-amino-and 1 mercapto-7,8,9,10-tetrahydro-6h-dibenzo[b,d]pyrans"; J. of Med. Chem.; vol. 20(1); 17-24; 1977; XP00211825
	Maurer M, Henn V, Dittrich A, Hofmann A.; "Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial."; Eur. Arch. Psychiat. Clin. Neurosci. (1990), 240:1-4. **(abstract only)**
	Mavromoustakos, T. et al; "Studies on the thermotropic effects of cannabinoids on phosphatidylcholine bilayers using differential scanning calorimetry and small angle X-ray diffraction"; Biochimica et Biophysica Acta; vol 1281(2); 1996; XP002111823
	1 **Mechoulam et al; Structural Requirements for Binding of Anandamide Type Compounds to the Brain Cannabinoid Receptor; J. Med. Chem.; 1997; 40; 659-667**
	Mechoulam et al; "Stereochemical Requirements for cannabinoid activity"; J. Med. Chem.; 23(10); 1068-1072; (1980)

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/600,786	Inventor Alexandros Makriyannis et al	
	Title Cannabimimetic Lipid Amides as Useful Medications		
	Filing Date 07/21/2000	Group Art Unit 1614	Docket No. UCONAP/145/PC/US

20	Mechoulam et al; "Synthesis of the individual, pharmacologically distinct, enantiomers of a tetrahydrocannabinol derivative"; Tetrahedron Asymmetry; 1: 311-314; (1990) **(abstract only)**
	*** *Mechoulam et al; "*Synthesis of the individual, pharmacologically distinct, enantiomers of a tetrahydrocannabinol derivative."; *Tetrahedron Asymmetry; 1: 315-318; (1990)*
	*** *Mechoulam, "Cannabinoids as therapeutic agents"; CRC press, 1986*
	1 **Melck, D., Bisogno, T., DePetrocellis, L., Chuang, H., Julius, D., Bifulco, M., DiMarzo, V.; "Unsaturated Long-Chain N-Acyl-vanillyl-amides"; Biochemical and Biophysical Res. Commun.; (1999); 262(1); 275-284. (abstract only)**
	Meltzer et al; "An improved synthesis of cannabinol and cannabiorcol"; Synthesis; 1981:985 (1981)
	Melvin et al; "Structure-Activity Relationships Defining the ACD-Tricyclic Cannabinoids Cannabinoid Receptor Binding and Analgesic Activity"; Drug Design and Discovery; 13(2); 155-166 (1995). **(abstract only)**
	Melvin et al; "Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs"; Mol. Pharmacol.; 44(5); 1008-1015 (1993) **(abstract only)**
	Merck Index; 11th edition; "Tetrahydrocannabinols" compound no. 9142; 1989
	*** *Morgan Dr: Therapeutic Uses of Cannabis. Harwood Academic Publishers, Amsterdam. (1997).*
	*** *Morris, S,; Mechoulam, R.; and Irene, Y., Halogenation of phenols and Phenyl ethers with Potassium Halides in the Presence of 18-Crown-6 on Oxidation with m-Chloroperbenzoic Acid, J. Chem. Soc., Perkin Trans. 1 1987, 1423-1427*
	Muller-Vahl KB, Kolbe H, Schneider U, Emrich, HM Cannabis in movement disorders. Porsch. Kompicmentarmed (1999) 6 (suppl. 3) 23-27. **(abstract only)**
	Muller-Vahl KB, Schneider U, Kolbe H, Emrich, HM.; "Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol." Am. J. Psychiat.; (1999); 156(3); 495.
	*** *Nahas G, Marijuana and Medicine; 1999, Human Press Inc., Totowa, NJ*
	1 **Neunhoeffer O., Gottschlich R.; "Acylating activity of O-acylated hydroxylamine derivatives"; Justus Liebigs Ann. Chem.; 736; 100-109; 1970; in German with English abstract**

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/600,786	Inventor Alexandros Makriyannis et al	
	Title Cannabimimetic Lipid Amides as Useful Medications		
	Filing Date 07/21/2000	Group Art Unit 1614	Docket No. UCONAP/145/PC/US

	Novak, J et al; "Cannabis, part 27, synthesis of 8-, 10- and 11-oxygenated cannabinoids; J. Chem. Soc. Perkin Trans.; 2867-2871; (1983) **(abstract only)**
	Nye et al; "High affinity cannabinoid binding sites in brain membranes labelled with [H]-5'-trimethylammonium delta8-tetrahydrocannabinol"; J. Pharmacol. Exp. Ther.; vol. 234(3); 784-791; 1985
	Pacheco M, et al; "Aminoalkylindoles: Actions On Specific G-Protein-Linked Receptors"; J. Pharmacol. Exp. Ther.; vol. 257, no. 1, pp. 170-183 and 172 Table (1991).
	Palmer et al; "Natural and Synthetic Endocannabinoids and Their Structure-Activity Relationships"; Current Pharmaceutical Design; 6; 1381-1397; (2000)
	Papahatjis et al; "A new ring-forming methodology for the synthesis of conformationally constrained bioactive molecules"; Chemistry Letters, 192; (2001)
	Papahatjis et al; "Pharmacophoric requirements for cannabinoid side chains: multiple bond and C1'-substituted delta8-tetrahydrocannabinols"; J. Med. Chem.; 41(7); 1195-1200; (1998)
	Pertwee et al; "AM630, a competitive cannabinoid receptor agonist"; Life Sci. 1995, 56(23/24), 1949-1955; XP 000653566
	Pertwee et al; "Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens"; Eur. J. Pharmacol. 1995, 284, 241-247; XP-001041044
	***1* Pertwee et al; "Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine"; Br. J. Pharmacol.; 105(4); 980-984 (1992). (abstract only)**
	Pertwee; Pharmacology of cannabinoid CB1 and CB2 receptors"; Pharmacol. Ther., vol. 74(2); pp129-180; (1997); XP002226467
	Petrov, M.L., Terent'eva, N.A., Potekhin, K.A., Struchkov, Yu. T.; ".alpha.,.beta.-unsaturated thiolates and their analogs in cycloaddition reactions. XVIII. Reaction of (2-phenylethynyl)tellurolates with C-ethoxycarbonyl-N-Phenylnitrilimine"; Zhurnal Organicheskoi Khimii; 29(7); 1372-1378; (1993) **(abstract only)**
	******* *Pinnegan-Ling D, Musty R.; Marinol and phantom limb pain: a case study. Proc Inv. Cannabinoid Rea. Sec. (1994):53.*

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/600,786	Inventor Alexandros Makriyannis et al	
	Title Cannabimimetic Lipid Amides as Useful Medications		
	Filing Date 07/21/2000	Group Art Unit 1614	Docket No. UCONAP/145/PC/US

	***1* Pinto et al; Cannabinoid Receptor Binding and Agonist Activity of Amides and Esters of Arachidonic Acid; Mol. Pharmacol.; 1994; 46(3); 516-522. (abstract only)**
	***1* Piomelli D., Beltramo M., Glasnapp S., Lin S.Y., Goutopoulos A., Xiw X-Q., Makriyannis A.; "Structural determinants for recognition and translocation by the anandamide transporter"; Proc. Natl. Acad. Sci. USA; 96; 5802-5807; (1999)**
	Pitt et al; "The synthesis of Deuterium, carbon-14 and carrier free tritium labelled cannabinoids"; Journal of Labellled Compounds; vol. 11(4); 551-575; 1975; XP002123229
	***1* Porreca F., Mosberg H.I., Hurst R., Hruby V.J., Burks T.F.; "Roles of mu, delta and kappa opiod receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse"; J. Pharmacol. Exp. Ther.; 230(2); 341-348; (1994). (abstract only)**
	Razdan et al; "Drugs derived from cannabinoids. 6. .Synthesis of cyclic analogues of dimethylheptylpyran"; J. Med. Chem.; vol. 19(5); 719-721; 1976 **(abstract only)**
	***1* Razdan et al; "Pharmacological and Behavioral Evaluation of Alkylated Anandamide Analogs"; Life Sci.; 1995; 56(23-24); 2041-2048 (abstract only)**
	Reggio et al; "Characterization of a region of steric interference at the cannabinoid receptor using the active analog approach"; J. Med. Chem. United States; vol. 36(12); 1761-1771; 1993
	Rhee, M. H.; Vogel, Z.; Barg, J.; Bayewitch, M.; Levy, R.; Hanus, L.; Breuer, A.; and Mechoulam, R.; "Cannabinol Derivatives: Binding to Cannabinoid Receptors and Inhibition of Adenylcyclase"; J. Med. Chem. 1997, 40(20); 3228-3233
	Rice AS. Cannabinoids and pain. Curr Opin Investig Drugs. 2001 Mar;2(3):399-414. **(abstract only)**
	Richardson JD, Aanonsen I, Hargreaves KM; "Antihyperalgesic effects of a spinal cannabinoids"; Eur. J. Pharmacol. (1998) 346:145-153.
	Richardson JD, Kilo S. Hargreaves KM; "Cannabinoids reduce dryperalgesia and inflammation via interaction with peripheral CB1 receptors"; Pain (1998) 75:111-119.
	Rinaldi-Carmona et al; "Biochemical and pharmacological characterization of SR141716A, the first potent and selective brain cannabinoid receptor antagonist"; Life Sci.; vol. 56(23/24); 1941-1947 (1995)

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/600,786	Inventor Alexandros Makriyannis et al	
	Title Cannabimimetic Lipid Amides as Useful Medications		
	Filing Date 07/21/2000	Group Art Unit 1614	Docket No. UCONAP/145/PC/US

	Rinaldi-Carmona et al; "SR141716A, a potent and selective antagonist of the brain cannabinoid receptor"; FEBS Lett.; 350; 240-244; (1994)
	Rompp Chemie Lexikon; Falbe and Regitz; "band 1-A-C1, 8"; Aufl, Thieme Verlag; Stuttgart, S 569-570; 1989
	Santus, Maria; "Studies on thioamides and their derivatives. IX. Synthesis of the derivatives of 1,2,4,5-tetrazine"; Acta Polonae Pharmaceutica; 50(2-3); 183-188; 1993 **(abstract only)**
	Schatz AR et al; "Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system"; Toxicol Appl Pharmacol. 1997 Feb; 142(2):278-87
	*** *Schuel, H., Burkman, L.J., Picone, R.P., Bo, T., Makriyannis, A., Cannabinoid receptors in human sperm. Mol. Biol. Cell., (1997) (8), 325a.*
	***1* Serdarevich B., Caroll K.K., "Synthesis and characterization of 1- and 2-monoglycerides of anteiso fatty acids"; J. Lipid Res.; 7; 277-284; (1966)**
	Shawali, A.S., Albar, H.A.; "Kinetics and mechanism of dehydrochlorination of N-aryl-C-ethoxycarbonyl formohydrazidoyl chlorides"; Canadian Journal Of Chemistry; 64(5); 871-875; 1986 **(abstract only)**
	Shen M. Thayer SA: Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol (1996) 54:459-462.
	Shim et al; "Three-dimensional quantitative structure-activity relationship study of the cannabimimetic (aminoalkyl)indoles using comparative molecular field analysis"; J. Med. Chem.; 1998, 41(23); 4521-4532; XP-002212407
	Shim et al; "Unified pharmacophoric model for cannabinoids and aminoalkylindoles derived from molecular superimposition of CB1 cannabinoid receptor agonists CP55244 and WIN55212-2"; ACS Symposium series, 1999 719 (rational drug design), 165-184; XP-001095771
	Showalter et al; "Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands""; J. Pharmacol. Exp. Ther., 1996 278(3) 989-999; XP-001097918
	Simiand J, Keane M, Keane PE, Soubrie P: SR 141716, A CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav. Pharmacol (1998) 9:179-181. **(abstract only)**

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/600,786	Inventor Alexandros Makriyannis et al	
	Title Cannabimimetic Lipid Amides as Useful Medications		
	Filing Date 07/21/2000	Group Art Unit 1614	Docket No. UCONAP/145/PC/US

	Tetko, I. V. et al; "Volume Learning Algoritm Artificial Neural Networks For 3D QSAR Studies"; J. Med. Chem.; vol. 44, no. 15 (2001) pp. 2411-2420, 2413, 2414 Table 1.
	Terranova J-P, Storme J-J Lafon N et al; "Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716"; Psycho-pharmacol (1996) 126:165-172 **(abstract only)**
	Tius et al; "Conformationally restricted hybrids of CP-55,940 and HHC: Steroeselective synthesis and activity"; Tetrahedron; 50 (9); 2671-2680; (1994) **(abstract only)**
	Ueda, N., Endocannabinoid hydrolases. Prostaglandins & Other Lipid Mediators 2002;68-69:521-534 **(abstract only)**
	***1* Vogel Z., Barg J., Levy R., Saya D., Heldman E., Mechoulam R.; "Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase"; J. Neurochem.; 61(1) 352-355; (1993) (abstract only)**
	Wagner JA, Varga K, Jarai Z, Kunos G; "Mesenteric vasodilation mediated by endothelia anandamide receptors"; Hypertension (1999) 33:429-434.
	Watanabe, T.; Miyaura, N.; and Suzuki, A.; "Synthesis of Sterically Hindered Biaryls via the Palladium Catalyzed Cross-Coupling Reaction of Arylboronic Acids or their Esters with Haloarenes"; Synlett 1992, 207-210
	Wiley et al; "Structure activity relationships of indole and pyrrole derived cannabinoids"; J. Pharmacol. Exp. Ther. 1998, 285(3), 995-1004; XP-001097982
	Wilson et al; "9-nor-delta8-tetrahydrocannabinol, a cannabinoid of metabolic intersts"; J. Med. Chem.; 17(4); 475-476; (1974)
	Wilson et al; "Analgesic properties of the tetrahydrocannabinols, their metabolites and analogs"; J. Med. Chem.; 18(7); 700-703; (1975)
	Wilson et al; "9-nor-9-hydrohexahydrocannabinols. Synthesis, some behavioral and analgesic properties, and comparison with the tetrahydrocannabinols"; J. Med. Chem.; 19(9); 1165-1167; (1976)
	Yamada et al; "(Aminoalkyl)indole isothiocyanates as potentiual electrophilic affinity ligands for the brain cannabinoid receptor"; J. Med. Chem. 1996, vol. 39(10), 1967-1974
	Yan, Guo et al; "Synthesis and pharmacological properties of 11-hydroxy-3-(1'-1'-dimethylheptyl)hexahydrocannabinol: a high affinity cannabinoid agonist"; J. Med. Chem.; vol. 37(16); 2619-2622; (1994)

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/600,786	Inventor Alexandros Makriyannis et al	
	Title Cannabimimetic Lipid Amides as Useful Medications		
	Filing Date 07/21/2000	Group Art Unit 1614	Docket No. UCONAP/145/PC/US

JF	Yan Guo et al; "(-)-11-hydroxy-7'-isothiocyanato-1'-1'dimethylheptyl-delta8-THC: a novel probe for the cannabinoid receptor in the brain"; J. Med. Chem.; 37(23); 3867-3870; (1994)

Examiner	Date Considered
Cary	8/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

AYR 11/03